InvestorsHub Logo
Followers 2
Posts 436
Boards Moderated 0
Alias Born 01/14/2014

Re: None

Thursday, 02/23/2017 3:33:31 PM

Thursday, February 23, 2017 3:33:31 PM

Post# of 807
Conclusions: Both CPM and TroVax induced highly beneficial anti-tumor immune responses resulting in significantly prolonged survival of end-stage CRC patients without toxicity. This is the first study to show a clear benefit of immunotherapy in advanced CRC, and suggests this approach may be superior (and less toxic) to continuous palliative chemotherapy in these patients.